

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2023/2024 influenza season

as of September 3, 2025

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	2 (0.4%)	6 (0.5%)	6 (0.5%)	0	0	297 (100%)	4 (0.5%)	0	0	0	0	334 (100%)	0	0	0	0	0
Number of viruses tested	529	1,159	1,159	293	293	297	794	332	332	332	332	334	342	201	201	201	201
Number of viruses reported	2,212						3,724						2,199				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.
NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.
Amantadine was examined by M2 sequencing.